Dalazatide (TFA)

CC[C@H](C)[C@@H]1NC([C@H](CSSC[C@H](NC([C@@H](NC(CNC(C2CSSC[C@@H]3NC([C@H](CCC(N)=O)NC([C@H](Cc4ccccc4)NC([C@H](C)NC([C@@H](NC([C@H](CSSC[C@H](NC([C@H](Cc5ccccc5)NC([C@H](CO)NC([C@H](CC(C)C)NC([C@H](CCCNC(N)=N)NC([C@H](Cc6ccc(O)cc6)NC([C@H](CCCCN)NC([C@H](CCSC)NC([C@H](CO)NC([C@H](Cc7c[nH]cn7)NC([C@H](CCCCN)NC3=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)C(NC(CCCNC(N)=N)C(NC(CCCCN)C(N[C@@H]([C@@H](C)O)C(N2)=O)=O)=O)=O)NC([C@H](CCCNC(N)=N)NC([C@H](CO)NC([C@H](CCCCN)NC([C@@H]8CCCN8C([C@@H](NC([C@@H](NC([C@H](CC(O)=O)NC1=O)=O)[C@@H](C)O)=O)[C@@H](C)CC)=O)=O)=O)=O)=O)=O)[C@@H](C)O)=O)=O)=O)=O)=O)=O)[C@@H](C)O)=O)C(N)=O)NC([C@H](CO)NC([C@@](N(C(C)=O)C([C@@H](N)Cc9ccc(OP(O)(O)=O)cc9)=O)(CCCNC(N)=N)OCCOCCN)=O)=O)=O.OC(C(F)(F)F)=O.[x]

[1]Olsen C, et al. Dalazatide (ShK-186), a first-in-class peptide inhibitor of Kv1. 3 potassium channels, demonstrates safety, tolerability and proof of concept of efficacy in patients with active plaque psoriasis. J. Invest. Dermatol., 2016, 136 (8) .|[2]Stevens A M, et al. Thu0285 Dalazatide, an Inhibitor of the KV1. 3 Channel on Activated Effector Memory T Cells, Has Immunotherapy Potential in Systemic Lupus Erythematosus. 2016.|[3]Matheu MP, et al. Imaging of effector memory T cells during a delayed-type hypersensitivity reaction and suppression by Kv1.3 channel block. Immunity. 2008 Oct 17;29 (4) :602-14.